Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

Sanofi announced that it has entered into an agreement to acquire Origimm Biotechnology GmbH.

With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline.

The transaction will add ORI-001 to Sanofi‚Äôs early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Ph1/2 trial to start in 2023.  

Read more